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Telomere maintenance is a prerequisite for immortalisation, and in most malignant cells is carried out by telomerase, an enzyme that
synthesises new telomeric repeats on the chromosome ends. In normal or reactive tissues with a high regenerative capacity,
telomerase is regulated according to the telomere loss that occurs during proliferation. To evaluate the interaction of proliferation
and telomerase activity in malignant lymphomas, we quantified telomerase expression in different non-Hodgkin lymphomas in
comparison to normal or reactive lymph nodes. Surprisingly, the activity levels were the same in most of the lymphomas analysed as
compared to reactive lymph nodes. Significantly higher activity was detected only in Burkitt’s lymphoma. Telomerase activity
correlated well with hTERT and c-myc expression, but was independent of proliferation. To evaluate interactions of telomere-binding
protein expression on telomerase expression in non-Hodgkin lymphoma, the mRNA levels of TRF1, TRF2, tankyrase and hPif1 were
assessed by real-time RT–PCR. We demonstrate here that the magnitude of telomerase upregulation does not necessarily reflect the
requirement of telomere compensation caused by proliferation. Telomerase regulation in non-Hodgkin lymphomas is therefore
uncoupled from proliferative stimuli found in reactive lymphoid tissue. We suggest that the upregulation of specific telomere-binding
proteins like TRF2 may contribute to telomere maintenance in malignant lymphoma.
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The telomeres of somatic cells shorten with each cell division due
to the ‘end-replication-problem’. Critically short telomeres induce
an irreversible exit from the cell cycle, called senescence. Telomere
loss is thus considered as a ‘mitotic clock’ that limits the
proliferative capacity of somatic cells (Blackburn, 1991). Immortal
cells such as stem cells and tumour cells express the enzyme
telomerase that compensates telomere loss by adding new telomere
repeats to the chromosomal ends. The expression of telomerase
activity is therefore a crucial step towards an immortal phenotype
during malignant transformation (Krupp et al, 2000). Telomerase
activity can be detected in a variety of malignant cancers
(Klingelhutz, 1997). Additional to ‘immortal’ cells, telomerase
activity can also be detected in tissues with a high regenerative
capacity such as lymphocytes, the basal layers of the skin
epithelium or the endometrium (Buchkovich and Greider, 1996;
Harle-Bachor and Boukamp, 1996; Bonatz et al, 1998). Telomerase
activity in benign tissues is upregulated in telomerase-competent
cells if proliferation occurs, for example, upon an in vitro (Belair
et al, 1997) or in vivo stimulation (Bonatz et al, 1998).
Lymphocytes expand clonally during the response to antigenic
challenge in the specific microenvironment of the germinal centre
(GC). During this extensive cell expansion, telomerase activity is
upregulated in the proliferating compartment of the GC, the
centroblasts (Weng et al, 1997). Unique to the GC reaction is the
telomere elongation that occurs during telomerase activation.
Centrocytes, GC cells that have already finished proliferative
expansion, express lower levels of telomerase activity and still have
longer telomeres than pre-GC naive B cells (Weng et al, 1997;
Norrback et al, 2001). It is believed that the telomere elongation in
the GC is a prerequisite for the lifelong ability of the immune
system to expand a few or even a single antigen-specific B cell
upon antigen encounter (Weng, 1999). Telomerase knockout mice
do indeed show a reduced formation of GC in the late-generation
mice, most likely caused by the inability of lymphocytes to restore
their telomere length in the GC (Herrera et al, 2000).
Nearly 90% of non-Hodgkin lymphomas (NHLs) are B-cell NHL
(B-NHL), of which the majority arise from GC cells or post-GC
mature B cells, indicated by their immune phenotype as well
as their mutated V-region of the immune globulin genes (Kuppers
et al, 1999). Ongoing somatic hypermutation indicates the
GC origin of the lymphoma for example, in follicular lymphoma
(FL), 50% of the diffuse large B-cell lymphomas (DLBL)
and Burkitt lymphomas. B-NHL of GC origin comprise over 70%
of all B-NHL. A pre-GC origin is postulated for a subset of
B-cell chronic lymphocytic leukaemia and for mantle cell
lymphoma (MCL), cases that show unmutated Ig genes. Plasma
cell myelomas on the other hand arise from post-GC cells (Kuppers
et al, 1999).
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the GC under normal conditions, (ii) telomerase activity and
telomere maintenance are a prerequisite for immortalisation and
(iii) B-NHL predominantly arise from GC-cells, it is tempting to
speculate that upregulation of telomerase and the associated events
in the GC represent an ‘Achilles’ heel’, which–if altered–leads to
immortalisation of lymphoid cells. Telomerase activity can be
detected in most cancers (Kim et al, 1994) as well as in lymphoma
tissues (Norrback et al, 1996; Ely et al, 2000). The activity was
reported to be positively correlated to the proliferation of the
lymphoma (Ely et al, 2000).
This study was initiated to evaluate the mechanism and the
extent of telomerase upregulation in lymphomas. The results may
render an insight into the transformation process of NHL. In
addition, we evaluated lymphomas as possible targets for
telomerase inhibition drug therapy, which is discussed as a
promising new approach in the treatment of several malignancies
(Damm et al, 2001).
MATERIAL AND METHODS
Samples
From all lymphomas studied, fresh and paraffin-embedded
samples as well as the relevant diagnostic cytogenetic information
were available. Fresh specimens were obtained during surgery,
overlayered with PBS, shock-frozen in liquid nitrogen and
maintained at  801C until use. The lymphomas were diagnosed
on the basis of Kiel and the recent WHO classification. The
diagnoses were confirmed by the reference pathologists of the
Lymph Node Registry Kiel on the basis of standard histopathology
and appropriate immunohistochemical stainings using the alkaline
phosphatase-anti-alkaline phosphatase (APAAP) technique with
mouse monoclonal antibodies. Immunoreagents were all pur-
chased from DAKO (Hamburg, Germany), except for anti-CD20,
Ki-S2 (detection of repp86) and Ki-S5 (detection of Ki67), which
had been generated at the Institute for Hematopathology, Kiel
(Kreipe et al, 1993a; Heidebrecht et al, 1997).
Telomerase activity assay (TRAP)
Frozen samples were crushed with a sterile micropistill in ice-cold
lysis buffer (CHAPS 0.5%, 10mM Tris-HCl (pH 7.5), 1mM MgCl2,
1m M EGTA, 5mM b-mercaptoethanol, 0.01mM AEBSF, 1Uml
 1
RNAsin (Promega), 10% glycerol). After incubation for 30min on
ice, the samples were centrifuged for 30min at 41C with 20.000g.
The supernatant was snap-frozen in liquid nitrogen and stored at
 801C. The protein concentration of the extracts was determined
by the Bradford assay.
The extracts were diluted appropriately and 200ng of protein (in
2ml) was mixed with 48ml reaction mix containing 20mM Tris-HCl
(pH 8.0), 1mM EGTA, 0.0005% Tween 20, 1.5mM MgCl2,6 3 m M
KCl, 50mM each dNTP, 2U Taq, 0.001amol ITAS, 10pmol TS-
Primer (50-TAMRA labelled) and 10pmol Cxext Primer (Krupp
et al, 1997).
After a 30-min incubation at 301C, the PCR conditions were as
follows: 951C for 3min and 36 cycles of 951C for 30s, 501C for 30s
and 721C for 30s. The PCR products were analysed on an ABI
prism 310 capillary electrophoresis unit as described (Krupp et al,
1997). The area under the first five telomerase peaks was added
and divided by the area under the internal amplification standard
(ITAS) peak. For semiquantitative measurement, a dilution series
of Hl60 extract was analysed in parallel. Linear regression analysis
of the telomerase peak/ITAS ratios of the dilution series was
performed (GraphPad Prim). The experimental samples were
expressed as corresponding nanograms of Hl60 protein.
TaqMan RT–PCR and LightCycler RT–PCR
Total RNA was extracted using the RNAzol Method. RNA (500ng)
was used for c-DNA synthesis using the First Strand Synthesis Kit
(Invitrogen) and random priming. The resulting c-DNA was
diluted 1:1 with TE buffer and 2ml was used in each TaqMan PCR.
A 7700 Sequence Detection System (Applied Biosystems) was used.
The primer and probes are shown in Table 1. A 50ml PCR sample
contained reagents of the TaqMan PCR Core Reagents Kit (PE
Biosystems) as recommended by the manufacturer, 10pmol of
each primer and 3pmol of the corresponding probe. For all targets,
the PCR conditions were 951C for 10min, followed by 40 cycles of
951C for 10s and 601C for 1min. As a control and for the
calculation of target amount in the experimental samples, DNA
fragments of the target genes were amplified using the correspond-
ing primer pairs and gel purified. A dilution series of these
fragments was used in each TaqMan PCR in separate tubes and
served as a standard curve (equivalent to 0.2, 0.005, 0.0125,
0.003125, 0.00078125 and 0.0001953125amol of pure DNA). After
setting a threshold cycle, the TaqMan automatically calculates a
linear regression of the standard curve of which the absolute
amounts are known, and interpolates the values for the experi-
mental samples. These are then expressed as attomol with respect
to the standard curve. The value for the target gene was then
divided by the value for b-actin that was generated in the same
way. By using the DNA dilution series, a comparison of
independent PCRs can be reliably performed.
For the detection of hTERT expression, a Lightcycler RT Kit
(Roche) was used as recommended by the manufacturer. The
primers and probe are designed to detect only biologically active
full-length mRNA.
Statistical analysis
Analysis of variance (one-way ANOVA), correlation analysis and
linear regression were calculated using GraphPad Prism version
3.00 for Windows, GraphPad Software, San Diego California, USA.
Table 1 Primers and TaqMan probes
Gene Primer Probe
TRF1 F: TCCTCTgCCTCTCTCTTTgC CCAgTCTAACAgCTTGCCAgTTgAgAAC
R: ggTTTTTCCTgCTgCAATTC
TRF2 F: CTgAgCTCACACCACTggAA ACTgACAgAAgCAgTggTCgAACCAgT
R: gCATCTTCTgCTggAAggTC
Tankyrase F: TgCATCCCAAACgTAAACAA-30 ACCAAgggTgTCCAgTgCATTCATCT
R: ggTCAgAgCCgTAACCAgC-30
hPif F: gCCTCACCCACAAAgAgAAg-30 ACTggAgTAggCAggCAgTgTCCCCT
R: CCTgAAAggAgggATgTTCA
c-myc F: ACCACCAgCAgCgACTCTgA ACCTTTTgCCAggAgCCTgCCTC
R: TCCAgCAgAAggTgATCCAgACT
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Immunohistochemistry for proliferation was performed using
monoclonal antibodies generated at the Institute for Hemato-
pathology, Kiel. Detection of Ki-67 was elaborated with the
antibody Ki-S5 (Kreipe et al, 1993b).The antibody Ki-S2 detects
the antigen repp86, which is restrictedly expressed in the S-, G2-
and M-phase of the cell cycle (Heidebrecht et al, 1997). Staining
with Ki-S2 was performed as described (Rudolph et al, 1998).
For calculation of the proliferative index, a representative but
randomly chosen area of the lymphoma was examined with  400
magnification. In all, 1000 cells were counted and cells with
positive nuclei were expressed as the percentage of all lymphoma
cells. Ki-67 and repp86 positivity were evaluated in corresponding
areas of the successive slides.
RESULTS
Telomerase activity levels are not correlated with
proliferation in B-cell non-Hodgkin lymphomas
The proliferation index of B-NHL was evaluated by immunohis-
tochemistry using two proliferation markers that have been
characterised extensively elsewhere (Kreipe et al, 1993b; Heideb-
recht et al, 1997). The antibody Ki-S2 recognizes the protein
repp86 that is exclusively expressed during S-, G2- and M-phase of
the cell cycle. In contrast, Ki-S5 recognizes the Ki-67 protein,
which besides being expressed in S-, G2- and M-phase is also
expressed in the G1-phase. The values for Ki-S2 positive cells are
therefore lower than the value for Ki-S5 positive cells and reflect
the number of actively cycling cells more precisely (Heidebrecht
et al, 1997; Rudolph et al, 1998). The proliferation determined by
Ki-S5 or Ki-S2 staining was significantly different between the
lymphoma subgroups (one-way analysis of variance, Po0.001 for
both antibodies) with low proliferation in the low-grade lympho-
mas (MCL, FL) and high proliferation in high-grade lymphomas
(DLBC, Burkitt) (Figure 1A and B). The proliferation index in the
group of MCL was very heterogeneous because four samples were
blastoid variants of MCL. The proliferation of benign lymph nodes
cannot be evaluated reliably because the proliferation is unequally
distributed in the tissue. Using a semiquantitative assay, we
evaluated telomerase activity in four different types of B-cell NHLs:
mantle cell lymphoma, follicular lymphoma, diffuse large B-cell
lymphoma and Burkitt lymphoma. Eight or seven samples of each
lymphoma subtype were studied. As a control, eight lymph nodes
with benign unspecific lymphadenitis were analysed. Telomerase
activity could be detected in seven out of eight benign lymph nodes
(range 1.6–49.0ng). The lymphoma samples showed activity in 25
of 31 samples with a broad range of activity levels from 2.8 to
566ng of the corresponding HL60 control. Four lymphomas were
telomerase negative (two FL and one DLBL). Two lymphomas
demonstrated unspecific PCR inhibition indicated by a suppres-
sion of the internal amplification standard.
Interestingly, the levels of activity in mantle cell lymphoma
(mean: 17.40; s.d.: 7.9), follicular lymphoma (mean: 5.40; s.d.: 3.60)
and diffuse large B-cell lymphoma (mean: 15.80; s.d.: 16.10) did
not differ significantly from the activity levels found in normal
lymph nodes (mean: 17.40; s.d.: 15.80) (Figure 1C). Including the
values for Burkitt’s lymphoma (mean: 261.4; s.d.: 202.7) in the
calculation, the data became statistically significantly different
from a random distribution (one-way analysis of variance,
Po0.001). If blastoid variants of MCL were compared to normal
MCL, no difference in telomerase activity was found (data not
shown) although blastoid MCL did present with a significantly
higher proliferation index (data not shown). These findings
indicate that MCL, FL and DLBL lymphoma express telomerase
activity levels that are undistinguishable from benign lymph nodes.
Burkitt’s lymphoma is the only B-NHL subtype analysed here,
which expresses significantly higher levels than benign lymph
nodes. Although there are obvious differences in the percentage of
proliferation cells between low-grade lymphomas (MCL, FL) and
DLBL, telomerase activity levels are similar (Figure 1C).
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Figure 1 Proliferation measured by staining for the Ki67 (A) antigen and
for repp86 (B). The percentage of positive cells was counted. In contrast to
the repp86 antigen (detected by Ki-S2), the Ki-67 antigen is also expressed
during G1-phase of the cell cycle. Thus, the values for Ki-67 are higher than
for repp86 staining (one-way analysis of variance, Po0.001 for both
antibodies). The proliferative index cannot be determined for benign lymph
nodes reliably because proliferation is unevenly distributed throughought
the tissue. (C) Telomerase activity measured by a semiquantitative TRAP.
The activity is expressed as nanograms of an HL60 control cell line. In total,
200ng experimental sample was used in each assay. No significant
differences were found between benign lymph nodes (benign), MCL, FL
and DLBL. High activity was measured in Burkitt’s lymphoma (Burkitt) (one-
way analysis of variance, Po0.001).
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c-myc expression
To explain the observed differences in telomerase activity between
Burkitt’s lymphoma and all other lymphomas analysed here, we
performed a real-time RT–PCR for the catalytic subunit of
telomerase hTERT. In most tumours and benign tissues studied
so far, hTERT expression correlates well with the expression of
telomerase activity (Figure 2A). HTERT levels did show a similar
expression pattern like telomerase activity (one-way analysis of
variance: Po0.001, correlation: P¼0.025). The low levels of
activity in MCL, FL and DLBL are thus most likely due to low
hTERT expression. Burkitt’s lymphoma did show high hTERT
expression accordingly (Figure 2A).
One of the best characterised transcription factors of the hTERT
gene is c-myc (Wang et al, 1998; Greenberg et al, 1999; Kyo et al,
2000; Xu et al, 2001). We performed a real-time RT–PCR to
determine the c-myc expression in the NHL samples. As expected,
the highest c-myc expression was found in Burkitt’s lymphoma
(Figure 2B). The t(8;14) translocation that is found in almost all
Burkitt’s lymphoma translocates the c-myc gene under the
influence of the immunoglobulin heavy chain promoter and thus
induces a c-myc overexpression (Kuppers et al, 1999). Altogether,
the c-myc expression shows a similar distribution compared to
telomerase activity and hTERT expression: high levels found in
Burkitt’s lymphoma and lower levels in benign lymph nodes, MCL,
FL and DLBL again with no relevant differences among benign
lymphnodes, MCL, FL and DLBL (one-way analysis of variance:
P¼0.0079, Figure 2C). These data suggest that the high telomerase
activity found in Burkitt’s lymphoma is probably caused by hTERT
overexpression. HTERT upregulation might be an effect of the high
c-myc levels. Similar levels of telomerase activity or hTERT in MCL
and FL indicate that the regulation of telomerase is independent of
a GC phenotype of the lymphoma.
Differential expression of telomere-binding proteins in
B-cell NHLs
If telomerase activity is needed for telomere length maintenance in
immortal cells, the requirement for such an activity should be
higher, the more and faster the cell divisions are carried out. As no
differences in telomerase activity and hTERT expression could be
detected in benign lymph nodes, MCL, FL and DLBL, although
high variations in the proliferative index were present, we
speculated that other mechanisms might contribute to telomere
maintenance in these lymphomas. A number of specific telomere-
binding proteins have been characterised so far. Among these are
negative regulators of telomere length such as TRF1 and TRF2
(Smogorzewska et al, 2000), as well as positive regulators like
tankyrase (Smith and De Lange, 2000). The helicase hPif1 has been
described as a telomerase inhibitor (Zhou et al, 2000). We studied
the expression levels of TRF1, TRF2 tankyrase and hPif1 in B-cell
NHL by TaqMan RT–PCR (Figure 3). TRF1 as well as tankyrase,
an inhibitor of TRF1, did not show significant differences in their
expression levels between all tissues examined, including Burkitt’s
lymphoma (one-way analysis of variance, P¼0.433 for TRF1 and
P¼0.508 for hPif1). TRF2 and hPif1 expressions were highest in
Burkitt’s lymphoma and showed only minor differences between
benign lymph nodes, MCL, FL and DLBL (one-way analysis of
variance: P¼0.0239 for TRF2, P¼0.0105 for hPif1). The level of
TRF2 as well as hPif1 correlated positively with telomerase activity
(correlation: P¼0.0455 and r¼0.8856 for TRF2 and P¼0.0128
and r¼0.9514 for hPif1, respectively). Taken together, these data
suggest a differential expression of TRF2 and hPif1 in NHL with an
upregulation in Burkitt’s lymphoma. Low levels without significant
differences were detected in benign lymph nodes, MCL, FL and
DLBL.
DISCUSSION
Telomeres are specialised structures at the chromosome ends that
(i) protect the ends from end-to-end fusion, (ii) impede the
double-strand break machinery to recognise the ends as breaks,
(iii) mediate correct pairing of the telomeres during mitosis and
meiosis and (iv) function as a buffer zone for the loss of terminal
DNA that occurs with each cell division (Pardue and Debaryshe,
1999). To circumvent telomere shortening, immortal cells, like
tumour cells or stem cells, express telomerase activity by
upregulating the expression of the catalytic subunit of the enzyme,
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Figure 2 (A) Telomerase activity measured by a semiquantitative TRAP
as shown in Figure 1C. (B) HTERT mRNA expression detected by real-
time RT–PCR using a LightCycler Assay. The expression level of hTERT in
the lymphomas is similar to telomerase activity (one-way analysis of
variance: Po0.0018, correlation: P¼0.0025, r¼0.9826). (C)C - myc
expression detected with real-time RT–PCR using a TaqMan assay. C-
myc is strongly overexpressed in Burkitt’s lymphoma, which carry the
t(8;14) translocation (one-way analysis of variance: P¼0.0079).
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shTERT. As telomerase upregulation is a feature of lymphocyte
expansion during the GC reaction and B-NHL frequently arise
from GC cells, we studied telomerase activity and hTERT
expression in B-NHL.
Several publications report on telomerase activity in B-cell
NHLs. In these studies, increased telomerase activity was found in
B-NHL compared to reactive lymph nodes. Furthermore, a positive
correlation of telomerase activity with the rate of proliferation in
the B-NHL was found (Norrback et al, 1996; Brousset et al, 1997;
Ely et al, 2000; Remes et al, 2000; Lin et al, 2001). In contrast to
these studies, we did not find an upregulation of telomerase
activity in most of the NHL compared to reactive lymph node
tissue (Norrback et al, 1996). The only NHL that showed
significantly higher telomerase activity was Burkitt’s lymphoma,
which expressed approximately 17  the activity found in reactive
lymph nodes, MCL, FL and DLBL.
To validate these data, we performed real-time RT–PCR
analysis of the catalytic subunit of telomerase hTERT, because in
most tissues and tumours studied so far, the presence and quantity
of full-length hTERT mRNA correlate well with telomerase activity
(Ulaner et al, 1998; Krams et al, 2001). Full-length hTERT
expression measured by real-time RT–PCR also correlated with
the levels of telomerase activity in our samples. Furthermore, a
known important transcription factor for the hTERT gene, c-myc,
did show a similar expression pattern like hTERT and telomerase
activity, respectively. We conclude that the upregulation of
telomerase activity found in Burkitt’s lymphoma is caused by a
transcriptional upregualtion of hTERT, which is most likely caused
by c-myc overexpression. The GC phenotype of a B-NHL
apparently does not necessarily evoke and is probably independent
of the level of telomerase activity and hTERT expression. MCL
express the same levels like DLBL, and FL express even at the
lowest levels. As within the group of lymphomas with constantly
low telomerase activity (MCL, FL, DLBL) the proliferation varied
substantially, a positive correlation of telomerase activity or
hTERT expression with proliferation cannot be found. Thus, in
contrast to reactive lymphocytes and the GC reaction, telomerase
activity and hTERT expression in malignant lymphomas seem to
be uncoupled from rates of proliferation (Buchkovich and Greider,
1996; Weng et al, 1996, 1997).
The discrepancies in our findings to the current literature
(Norrback et al, 1996; Ely et al, 2000) might be explained by the
use of a nonquantitative telomerase activity assay and the lack of
data on quantitative RT–PCR for hTERT in earlier studies. Our
telomerase activity assay is capable of detecting reproducibly small
differences and shows a broad linear range (Klapper et al, 1998).
Quantitative real-time RT–PCR analysis of hTERT strongly
supports our results on telomerase activity.
Theoretically, the need for telomerase activity to maintain
telomere length in an immortal cell clone is positively correlated to
the number of cell divisions that are carried out. In other words, a
high number of proliferating cells in a tumour would require
relatively high telomerase activity compared to tumours with low
proliferation. As the telomere length in most malignancies,
including B-NHL, is shorter than in the corresponding normal
tissue, a further shortening due to insufficient telomerase activity
would lead to cell death (Remes et al, 2000). Thus, maintenance of
telomere integrity seems even more critical for malignant than for
normal cells. The existence of an alternative telomerase-indepen-
dent mechanism for telomere length preservation (ALT) in the
lymphomas examined here cannot be ruled out completely. As no
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Figure 3 Telomere-binding protein expression detected by real-time
RT–PCR using TaqMan assays. The expression is indicated relative to b-
actin endogenous control: (A) TRF1 (one-way analysis of variance:
P¼0.433); (B) TRF2 (one-way analysis of variance: P¼0.0239), (C)
tankyrase (one-way analysis of variance: P¼0.508), (D) hPif1 (one-way
analysis of variance: P¼0.0105).
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samples, so far only indirect evidence can be obtained from the
telomere length pattern (Bryan et al, 1995; Dunham et al, 2000).
However, studies of telomere length pattern in B-NHL suggest
that most of the lymphomas have telomeres that point to a
telomerase-dependent pathway of telomere maintenance (Remes
et al, 2000).
The lack of correlation in telomerase activity and proliferation
in B-NHL found in this study, led us to examine telomere-binding
protein expression. A downregulation of negative telomere length
regulators in lymphomas with relatively high proliferation and
relatively low telomerase activity (e.g. DLBL) could balance
telomere loss and synthesis. Some of these proteins have been
shown to be negative regulators of telomere length in the presence
of telomerase activity (e.g. TRF1, hPif1 and to some extent TRF2)
(Smogorzewska et al, 2000; Zhou et al, 2000). Others like tankyrase
positively influence telomere length (Smith and De Lange, 2000).
The effect of these proteins seems mainly to be mediated by
altering the access of telomerase to its substrate, the telomere (van
Steensel and De Lange, 1997; Smogorzewska et al, 2000). We found
similar levels of TRF1 and tankyrase expression in all lymphomas
studied. Interestingly, similar low levels of TRF2 and hPif1 were
found in the samples with low telomerase activity (reactive lymph
nodes, MCL, FL, DLBL), while Burkitt’s lymphoma expressed
significantly higher levels. HPif1 is a helicase that directly
associates with telomeric DNA (Zhou et al, 2000). Overexpression
of Pif1p in yeast results in telomere shortening by inhibiting
telomerase-mediated telomere lengthening (Zhou et al, 2000).
TRF2, on the other hand, mainly functions in telomere end-
protection by mediating telomere folding to t-loops (van Steensel
et al, 1998; Griffith et al, 1999; Stansel et al, 2001) but if
overexpressed, TRF2 also negatively influences telomere length
(Smogorzewska et al, 2000). Interestingly, overexpressing TRF2 in
human primary cells protects critically shortened telomeres and
delays senescence (Karlseder et al, 2002). This is the first work that
determines telomerase expression and such a broad range of
telomere-binding protein expression in a quantitative manner in
malignant and reactive tissue. The upregulation of telomerase
activity in parallel with an upregulation of proteins that inhibit
telomerase-mediated telomere lengthening indicate that the
importance of high telomerase levels for maintenance of telomere
length might be overestimated. Telomerase upregulation might
just be a side effect of the high c-myc levels found in Burkitt’s
lymphoma, which again might cause high hTERT levels as shown
here. On the other hand, stabilisation of shorter tumour telomeres
might need higher levels of telomere-binding protein expression.
Upregulation of proteins that delay telomere damage signals like
TRF2 might play a key role in this process. Further studies of
tumours characterised quantitatively for telomerase activity,
telomere-binding protein expression and additionally telomere
length will provide more insight into the interaction of these three
components in the stabilisation of telomeres in malignant and
benign cells.
Telomerase inhibition is discussed as a promising approach for
treating a variety of malignant tumours. Two main prerequisites
should match if a tumour is suitable for telomerase-inhibition
therapy: (i) Telomerase activity must be detectable and must
therefore be the main mechanism of telomere maintenance. We
show here that the level of expression does not necessarily reflect
the requirement for telomere maintenance due to proliferation.
Thus, tumours with low telomerase activity also can be sensitive to
telomerase inhibition if (ii) telomeres of the tumour are
significantly shorter than telomeres of normal tissue, especially
of stem cells. In this case, inhibition of telomerase activity would
shorten tumour telomeres faster to a critical length than in normal
tissue and would therefore induce cell death selectively in tumour
cells (Remes et al, 2000). Adding a new layer of complexity, we
demonstrate, that telomere-binding protein expression varies in
NHLs. We propose that besides telomerase activity and telomere
length, telomere-binding protein expression also might influence
the efficiency of telomerase-inhibition therapy. High levels of TRF2
have been shown to prevent or delay the signalling of a critically
shortened telomere to induce senescence (Karlseder et al, 2002).
Therefore, tumours that overexpress TRF2-like Burkitt’s lympho-
ma, might be more resistant to telomerase-inhibition therapy. This
hypothesis has to be tested in cell culture models using the
currently available specific telomerase inhibitors in cell lines that
overexpress, for example, TRF2 or hPif1 (Damm et al, 2001; Corey,
2002).
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